Epizyme Inks Epigenetics Deal With Celgene; $90M Up Front
By Trista Morrison
Thursday, April 26, 2012
Epizyme Inc. is expected to announce early Thursday a broad epigenetics partnership with Celgene Corp. that brings the small biotech $90 million up front, at least $160 million in milestone payments per compound and double-digit royalties.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.